Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.

[1]  O. Landgren,et al.  MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia , 2014, Leukemia.

[2]  G. Vassilopoulos,et al.  Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders , 2014, Leukemia.

[3]  M. Cazzola,et al.  MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. , 2013, Blood.

[4]  E. Hsi,et al.  MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. , 2013, American journal of clinical pathology.

[5]  A. Tefferi,et al.  CME Information , 2013 .

[6]  M. Cazzola,et al.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. , 2013, Blood.

[7]  N. Munshi,et al.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.

[8]  J. Qian,et al.  Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. , 2013, Clinical biochemistry.

[9]  N. Gutiérrez,et al.  MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia , 2013, Leukemia.

[10]  C. Buske,et al.  How to manage Waldenstrom's macroglobulinemia , 2013, Leukemia.

[11]  L. Staudt,et al.  MYD88 L265P somatic mutation in IgM MGUS. , 2012, The New England journal of medicine.

[12]  N. Harris,et al.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.

[13]  M. Gertz,et al.  Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management , 2012, American journal of hematology.

[14]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[15]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[16]  F. Ricci,et al.  Factors predicting transformation of asymptomatic IgM monoclonal gammopathy. , 2011, Clinical lymphoma, myeloma & leukemia.

[17]  Kathleen M Murphy,et al.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. , 2010, The Journal of molecular diagnostics : JMD.

[18]  Dong Chen,et al.  Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia , 2009, Modern Pathology.

[19]  M. Dimopoulos,et al.  Waldenström's macroglobulinemia. , 2005, Best practice & research. Clinical haematology.

[20]  L. Medeiros,et al.  Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia: An Evolving Concept , 2005, Advances in anatomic pathology.

[21]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[22]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[23]  M. Dimopoulos,et al.  Waldenström's macroglobulinemia. , 1994, Hematology/oncology clinics of North America.

[24]  N. Weiss,et al.  Incidence of Waldenström's macroglobulinemia. , 1993, Blood.

[25]  I. Soubeyran,et al.  IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas , 2013, Leukemia.